This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
3/21/2022
Good day, and thank you for standing by. Welcome to the ORIC Pharmaceuticals fourth quarter and full year 2021 financial results and operational update call. At this time, all participants are on a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded, and if you require any further assistance, please press star 0. I want to hand the conference over to speaker today, Dominic Piccitelli, Chief Financial Officer. Please go ahead.
Good afternoon, and welcome to the Oreck Pharmaceuticals' fourth quarter and full year 2021 financial results and operational update call. Following the market close today, we filed our Form 10-K and issued a press release with our financial results for the fourth quarter and full year ended December 31st, 2021. You may find these documents posted on the investor page of orcfarmer.com. We have pre-recorded a portion of our prepared remarks, after which we will host a live Q&A session, so please bear with us if we have any technical difficulties. Before we begin, starting on slide two, during this conference call, we will be making forward-looking statements. OREC's actual results may differ materially from those expressed in or indicated by such forward-looking statements. For a description of risk factors associated with investing in OREC, please refer to our recent filing with the Securities Exchange Commission. OREC specifically disclaims any obligation to update any forward-looking statements except as required by law. Now turning to slide three, I'll briefly walk you through our agenda and introduce our speakers. During today's call, we'll primarily focus on an update on ORAC 101, after which we'll provide a pipeline update and summary, followed by Q&A. Joining me on the call today, we have Jacob Chaco, CEO, and Prateek Multani, CMO. Now, let me turn over the call to Jacob. Thank you, Dominic.
Turning to slide four. As you know, over the past two-plus years, we have conducted dose escalation and dose expansion studies, testing two separate therapeutic hypotheses, for GR inhibition as a means of overcoming resistance to chemotherapy in various cell tumors and to AR modulators in prostate cancer. We recently completed interim analyses from both combination studies, and we believe that further development of ORAC 101 should be discontinued due to a lack of sufficient efficacy signal to meet our benchmarks, which Prateek will tell you more about shortly. In both studies, we took on a difficult challenge, namely, in later line patients who had already progressed on a prior cancer therapeutic, we were attempting to add a GR antagonist in order to resensitize them to that prior therapeutic. While that was a high bar, it was an important clinical question to evaluate because of the limited treatment options available to those patients today. The challenges of assessing efficacy signal in a single-arm study of a combination regimen are obvious, So our team put in place two well-designed clinical trials that were complemented by a robust translational effort. We're confident that we've explored the GR hypothesis appropriately and also confident in making this decision. While we're obviously disappointed that ORIC 101 is not continuing, we're proud of the scientific rigor and thoughtful clinical design that allowed us to make an efficient but thorough decision. Despite the discontinuation of ORIC 101, we believe we have one of the most robust and differentiated pipelines in small-cap biotech. We've been intentional about assembling a broader pipeline of both novel and validated targets that are attempting to address areas of high unmet need with either first-in-class or potentially best-in-class approaches. Last year, we filed three INDs or equivalents for single-agent trials being initiated this year for ORIC 533 in multiple myeloma, OREC 114 in EGFR HER2 cancers, and OREC 944 in prostate cancer, with data from all three programs expected in the first half of 2023. Each of these programs has a unique angle or angles that we believe will help differentiate them in the clinic. Beyond these three clinical stage programs, our discovery research team last year advanced two programs in the lead optimization, one of which we recently introduced as our PLK4 program, which we believe is a first-in-class synthetic lethality approach for breast cancer. Finally, we've been thoughtful about bolstering our balance sheet and managing our resources efficiently, so we believe we're well-capitalized to weather a sustained market downturn. With the discontinuation of ORIC 101, our cash runway has now been extended from the first half of 2024 to the second half of 2024, and that guidance assumes advancement of all our pipeline programs. With that said, let me now turn the call over to Prateek to walk you through the summary highlights of the ORIC 101 studies.
You're reading a preview of the ORIC Q4 2021 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing